Updated April 19
Johnson & Johnson suffers another supply setback as vaccine maker suspends manufacturing
The pause in production, requested by the FDA, follows the contamination of 15 million doses of J&J vaccine in March.
By Chris RowlandThe Washington Post
Read Article
Emergent BioSolutions has shut down new manufacturing of Johnson & Johnson’s coronavirus vaccine at its Baltimore plant at the request of the Food and Drug Administration after an inspection of the troubled facility last week, Emergent said Monday.
The halt in production is another setback for Johnson & Johnson as it attempts to meet its promise to deliver nearly 100 million doses of vaccine to the U.S. government by the end of May.